Examiner-Initiated Interview Summary	Application No.	Applicant(s)
	09/884,392	CORNELISSEN ET AL.
	Examiner	Art Unit
	N. Bhat	1761
All Participants:	Status of Applicatio	n:
(1) <u>N. Bhat</u> .	(3)	
(2) Mr. McGowan.	(4)	
Date of Interview: 2 February 2004	Time:	
Type of Interview:  ☐ Telephonic ☐ Video Conference ☐ Personal (Copy given to: ☐ Applicant ☐ Applic  Exhibit Shown or Demonstrated: ☐ Yes ☐ No If Yes, provide a brief description:	cant's representative)	
Part I.		
Rejection(s) discussed: 112, 2 <sup>nd</sup> rejection on newly amended claims 4, 9.	•	
Claims discussed: 4, 9, 10 and 13		
Prior art documents discussed: None		
Part II.		
SUBSTANCE OF INTERVIEW DESCRIBING THE GENE See Continuation Sheet	ERAL NATURE OF WHAT	TWAS DISCUSSED:
Part III.		
<ul> <li>☑ It is not necessary for applicant to provide a separate directly resulted in the allowance of the application. The of the interview in the Notice of Allowability.</li> <li>☐ It is not necessary for applicant to provide a separate did not result in resolution of all issues. A brief summater</li> </ul>	ne examiner will provide a record of the substance	a written summary of the substance of the interview, since the interview
	·	
(Framinas/CDF Cignature)	t/Applicant/a Danssanta	ilyo Cianatura if anno i-t-)
(Examiner/SPE Signature) (Applicar	ivApplicant's Representat	ive Signature – if appropriate)

Application No. 09/884,392

Continuation of Substance of Interview including description of the general nature of what was discussed: In claims 4 and 9 applicant has used such as language which is a linking term, the examiner suggested deleting the recitation such as CitremLR10tm as this is trademarked and should not be used in claims. In claim 9, the such as lecithin was deleted but a dependent claim from claim 1 was suggested by applicant's rep to provide an emuslion according to claim 1 which is essentially free of lecithin which is now new claim 15. Claims 10 and 13 had minor typographical errors which were corrected by examiner's amendment. Changes to be made to the aforementioned claims were authorized by applicant's representative by Examiner's Amendment.